Somatostatin analogues in the treatment of breast and prostate cancer

Andrea Manni, Alice E. Boucher, Laurence M. Demers, Harold A. Harvey, Allan Lipton, Mary A. Simmonds, Mary Bartholomew

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Newly developed somatostatin analogues may be useful agents in the treatment of breast and prostate cancer. Potential mechanisms of antitumor action include suppression of circulating levels of trophic hormones and growth factors as well as direct effects at the tumor level, potentially involving autocrine/paracrine mechanisms. Pilot clinical trials conducted in heavily pretreated women with advanced breast cancer indicate that SMS 201-995 (Sandostatin®) has minimal toxicity and moderately suppresses stimulated growth hormone secretion and basal somatomedin-C level. Somatostatin analogues have also been found to retard the growth of experimental prostate cancer, particularly when used in combination with LHRH analogues. The therapeutic efficacy of these compounds used alone or in combination with other agents in the treatment of breast and prostate cancer remains to be established in larger clinical trials involving less heavily pretreated patients.

Original languageEnglish (US)
Pages (from-to)1083-1087
Number of pages5
JournalJournal of Steroid Biochemistry and Molecular Biology
Volume37
Issue number6
DOIs
StatePublished - Dec 20 1990

Fingerprint

Octreotide
Somatostatin
Prostatic Neoplasms
Breast Neoplasms
Hormones
Insulin-Like Growth Factor I
Gonadotropin-Releasing Hormone
Clinical Trials
Growth Hormone
Toxicity
Tumors
Intercellular Signaling Peptides and Proteins
Therapeutics
Growth
Neoplasms

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Endocrinology
  • Clinical Biochemistry
  • Cell Biology

Cite this

Manni, Andrea ; Boucher, Alice E. ; Demers, Laurence M. ; Harvey, Harold A. ; Lipton, Allan ; Simmonds, Mary A. ; Bartholomew, Mary. / Somatostatin analogues in the treatment of breast and prostate cancer. In: Journal of Steroid Biochemistry and Molecular Biology. 1990 ; Vol. 37, No. 6. pp. 1083-1087.
@article{07b68f5ed37745d3a423d2fe768330ec,
title = "Somatostatin analogues in the treatment of breast and prostate cancer",
abstract = "Newly developed somatostatin analogues may be useful agents in the treatment of breast and prostate cancer. Potential mechanisms of antitumor action include suppression of circulating levels of trophic hormones and growth factors as well as direct effects at the tumor level, potentially involving autocrine/paracrine mechanisms. Pilot clinical trials conducted in heavily pretreated women with advanced breast cancer indicate that SMS 201-995 (Sandostatin{\circledR}) has minimal toxicity and moderately suppresses stimulated growth hormone secretion and basal somatomedin-C level. Somatostatin analogues have also been found to retard the growth of experimental prostate cancer, particularly when used in combination with LHRH analogues. The therapeutic efficacy of these compounds used alone or in combination with other agents in the treatment of breast and prostate cancer remains to be established in larger clinical trials involving less heavily pretreated patients.",
author = "Andrea Manni and Boucher, {Alice E.} and Demers, {Laurence M.} and Harvey, {Harold A.} and Allan Lipton and Simmonds, {Mary A.} and Mary Bartholomew",
year = "1990",
month = "12",
day = "20",
doi = "10.1016/0960-0760(90)90470-6",
language = "English (US)",
volume = "37",
pages = "1083--1087",
journal = "Journal of Steroid Biochemistry and Molecular Biology",
issn = "0960-0760",
publisher = "Elsevier Limited",
number = "6",

}

Somatostatin analogues in the treatment of breast and prostate cancer. / Manni, Andrea; Boucher, Alice E.; Demers, Laurence M.; Harvey, Harold A.; Lipton, Allan; Simmonds, Mary A.; Bartholomew, Mary.

In: Journal of Steroid Biochemistry and Molecular Biology, Vol. 37, No. 6, 20.12.1990, p. 1083-1087.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Somatostatin analogues in the treatment of breast and prostate cancer

AU - Manni, Andrea

AU - Boucher, Alice E.

AU - Demers, Laurence M.

AU - Harvey, Harold A.

AU - Lipton, Allan

AU - Simmonds, Mary A.

AU - Bartholomew, Mary

PY - 1990/12/20

Y1 - 1990/12/20

N2 - Newly developed somatostatin analogues may be useful agents in the treatment of breast and prostate cancer. Potential mechanisms of antitumor action include suppression of circulating levels of trophic hormones and growth factors as well as direct effects at the tumor level, potentially involving autocrine/paracrine mechanisms. Pilot clinical trials conducted in heavily pretreated women with advanced breast cancer indicate that SMS 201-995 (Sandostatin®) has minimal toxicity and moderately suppresses stimulated growth hormone secretion and basal somatomedin-C level. Somatostatin analogues have also been found to retard the growth of experimental prostate cancer, particularly when used in combination with LHRH analogues. The therapeutic efficacy of these compounds used alone or in combination with other agents in the treatment of breast and prostate cancer remains to be established in larger clinical trials involving less heavily pretreated patients.

AB - Newly developed somatostatin analogues may be useful agents in the treatment of breast and prostate cancer. Potential mechanisms of antitumor action include suppression of circulating levels of trophic hormones and growth factors as well as direct effects at the tumor level, potentially involving autocrine/paracrine mechanisms. Pilot clinical trials conducted in heavily pretreated women with advanced breast cancer indicate that SMS 201-995 (Sandostatin®) has minimal toxicity and moderately suppresses stimulated growth hormone secretion and basal somatomedin-C level. Somatostatin analogues have also been found to retard the growth of experimental prostate cancer, particularly when used in combination with LHRH analogues. The therapeutic efficacy of these compounds used alone or in combination with other agents in the treatment of breast and prostate cancer remains to be established in larger clinical trials involving less heavily pretreated patients.

UR - http://www.scopus.com/inward/record.url?scp=0025697041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025697041&partnerID=8YFLogxK

U2 - 10.1016/0960-0760(90)90470-6

DO - 10.1016/0960-0760(90)90470-6

M3 - Article

C2 - 1981012

AN - SCOPUS:0025697041

VL - 37

SP - 1083

EP - 1087

JO - Journal of Steroid Biochemistry and Molecular Biology

JF - Journal of Steroid Biochemistry and Molecular Biology

SN - 0960-0760

IS - 6

ER -